Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
Dare Bioscience, Inc. (DARE)
Last dare bioscience, inc. earnings: 8/14 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.darebioscience.com/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018. Business Update “We are actively enrolling couples in our postcoital test clinical trial of Ovaprene®, our non-hormonal monthly contraceptive, and are preparing to commence the Phase2b program of Sildenafil Cream, 3.6%, our candidate for the treatment of female sexual arousal disorder. We are also advancing our development portfolio of other product candidates that we believe have the potential to deliver a first-in-category product addressing a persistent unmet need in women’s reproductive health, such as our vaginal ring technologies for hormone replacement and pregnancy maintenance and our vaginal tamoxifen for vulvar and vaginal atrophy in women with hormone receptor positive breast cancer,” said Sabrina Martucci Johnson, Pr
Show less
Read more
Impact Snapshot
Event Time:
DARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DARE alerts
High impacting Dare Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
DARE
News
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateGlobeNewswire
- Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024GlobeNewswire
- Dare´ Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingGlobeNewswire
- Daré Bioscience, Inc. (NASDAQ: DARE) was downgraded by analysts at Dawson James from a "buy" rating to a "neutral" rating.MarketBeat
DARE
Earnings
- 8/10/23 - Miss
DARE
Analyst Actions
- 2/2/24 - Dawson James
DARE
Sec Filings
- 3/28/24 - Form 424B5
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- DARE's page on the SEC website